Sprint Bioscience AB (publ) (SPRINT.ST)
SEK 1.6
(0.25%)
SEK 1.6
(0.25%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 41.78 Million SEK | 93.87% |
| 2022 | -60.9 Million SEK | -346.81% |
| 2021 | 24.67 Million SEK | 284.03% |
| 2020 | 6.42 Million SEK | -74.67% |
| 2019 | 25.36 Million SEK | 47.56% |
| 2018 | 17.19 Million SEK | -18.05% |
| 2017 | 20.97 Million SEK | -39.32% |
| 2016 | 34.57 Million SEK | 335.76% |
| 2015 | 7.93 Million SEK | 37.38% |
| 2014 | 5.77 Million SEK | -0.29% |
| 2013 | 5.79 Million SEK | 54.37% |
| 2012 | 3.75 Million SEK | 90.16% |
| 2011 | 1.97 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 9.07 Million SEK | 336.78% |
| 2024 Q3 | -4.5 Million SEK | -149.71% |
| 2024 Q1 | -3.83 Million SEK | 23.58% |
| 2023 Q2 | -1.24 Million SEK | 42.31% |
| 2023 Q3 | 37.81 Million SEK | 3134.51% |
| 2023 Q1 | -2.16 Million SEK | 85.59% |
| 2023 Q4 | -5.01 Million SEK | -113.26% |
| 2023 FY | -3.73 Million SEK | 93.87% |
| 2022 FY | -60.9 Million SEK | -346.81% |
| 2022 Q3 | -3.36 Million SEK | -0.54% |
| 2022 Q2 | -3.34 Million SEK | -5.29% |
| 2022 Q4 | -14.99 Million SEK | -345.9% |
| 2022 Q1 | -3.17 Million SEK | -44.82% |
| 2021 FY | 24.67 Million SEK | 284.03% |
| 2021 Q4 | -2.19 Million SEK | -107.23% |
| 2021 Q3 | 30.34 Million SEK | 1850.06% |
| 2021 Q2 | -1.73 Million SEK | -0.29% |
| 2021 Q1 | -1.72 Million SEK | -92.75% |
| 2020 Q1 | 2.48 Million SEK | -11.17% |
| 2020 FY | 6.42 Million SEK | -74.67% |
| 2020 Q4 | -897 Thousand SEK | -127.98% |
| 2020 Q2 | 1.63 Million SEK | -34.06% |
| 2020 Q3 | 3.2 Million SEK | 95.97% |
| 2019 Q3 | 2.34 Million SEK | -86.3% |
| 2019 FY | 25.36 Million SEK | 47.56% |
| 2019 Q4 | 2.79 Million SEK | 18.95% |
| 2019 Q2 | 17.13 Million SEK | 454.38% |
| 2019 Q1 | 3.09 Million SEK | 1846.33% |
| 2018 Q4 | -177 Thousand SEK | -104.51% |
| 2018 FY | 17.19 Million SEK | -18.05% |
| 2018 Q3 | 3.92 Million SEK | 2903.57% |
| 2018 Q2 | -140 Thousand SEK | -100.83% |
| 2018 Q1 | 16.8 Million SEK | 1232.99% |
| 2017 Q1 | 8.71 Million SEK | 3.87% |
| 2017 Q2 | 9.07 Million SEK | 4.18% |
| 2017 Q3 | 1.92 Million SEK | -78.74% |
| 2017 Q4 | 1.26 Million SEK | -34.63% |
| 2017 FY | 20.97 Million SEK | -39.32% |
| 2016 Q2 | 14.59 Million SEK | 374.08% |
| 2016 FY | 34.57 Million SEK | 335.76% |
| 2016 Q4 | 8.38 Million SEK | -1.45% |
| 2016 Q3 | 8.51 Million SEK | -41.7% |
| 2016 Q1 | 3.07 Million SEK | -10.24% |
| 2015 FY | 7.93 Million SEK | 37.38% |
| 2015 Q4 | 3.43 Million SEK | -11.09% |
| 2015 Q3 | 3.85 Million SEK | 197.0% |
| 2015 Q2 | 1.29 Million SEK | -38.96% |
| 2015 Q1 | 2.12 Million SEK | -6.6% |
| 2014 Q4 | 2.27 Million SEK | 148.19% |
| 2014 FY | 5.77 Million SEK | -0.29% |
| 2014 Q1 | 1.14 Million SEK | 31.76% |
| 2014 Q2 | 1.02 Million SEK | -10.08% |
| 2014 Q3 | 918 Thousand SEK | -10.53% |
| 2013 Q3 | 909 Thousand SEK | -54.92% |
| 2013 Q2 | 2.01 Million SEK | 0.0% |
| 2013 Q4 | 866 Thousand SEK | -4.73% |
| 2013 FY | 5.79 Million SEK | 54.37% |
| 2013 Q1 | 2.01 Million SEK | 0.0% |
| 2012 FY | 3.75 Million SEK | 90.16% |
| 2011 FY | 1.97 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 126.006% |
| Ziccum AB (publ) | -23.28 Million SEK | 279.451% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 87.934% |
| Mendus AB (publ) | 28.48 Million SEK | -46.688% |
| Genovis AB (publ.) | 54 Million SEK | 22.618% |
| Intervacc AB (publ) | -13.79 Million SEK | 402.936% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -1824.781% |
| Active Biotech AB (publ) | -1.67 Million SEK | 2594.746% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | -319.422% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | -55.8% |
| Aptahem AB (publ) | 2.63 Million SEK | -1488.468% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 1321.485% |
| Kancera AB (publ) | -1.96 Million SEK | 2226.565% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -54168.831% |
| Fluicell AB (publ) | 1.73 Million SEK | -2304.315% |
| Saniona AB (publ) | 11.78 Million SEK | -254.698% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 916.631% |
| Biovica International AB (publ) | 6.87 Million SEK | -507.634% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 279.474% |
| AcouSort AB (publ) | 8.38 Million SEK | -398.117% |
| Xintela AB (publ) | 78 Thousand SEK | -53473.077% |
| Abliva AB (publ) | -35.66 Million SEK | 217.172% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 128.446% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -1388.671% |
| OncoZenge AB (publ) | 3000.00 SEK | -1392800.0% |
| Amniotics AB (publ) | -1.93 Million SEK | 2265.13% |
| 2cureX AB (publ) | -37.48 Million SEK | 211.471% |
| CombiGene AB (publ) | -21.29 Million SEK | 296.269% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 9978.723% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 96.301% |
| Camurus AB (publ) | 1.58 Billion SEK | 97.356% |
| Corline Biomedical AB | 28.38 Million SEK | -47.241% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 134.047% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 221.421% |
| I-Tech AB | 27.56 Million SEK | -51.589% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 41.104% |
| Cyxone AB (publ) | 2.61 Million SEK | -1500.421% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -1127.946% |
| Biosergen AB | -456 Thousand SEK | 9263.816% |
| Cantargia AB (publ) | -3.45 Million SEK | 1310.866% |
| NextCell Pharma AB | -43.74 Million SEK | 195.517% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 554.503% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | -272.49% |
| Nanologica AB (publ) | -76 Thousand SEK | 55082.895% |
| SynAct Pharma AB | -778 Thousand SEK | 5471.08% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 21751.295% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 423.379% |
| Lipum AB (publ) | 53 Thousand SEK | -78743.396% |
| BioInvent International AB (publ) | 71.46 Million SEK | 41.525% |
| Alzinova AB (publ) | 19.87 Million SEK | -110.26% |
| Oncopeptides AB (publ) | 36.29 Million SEK | -15.119% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -2756.215% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 278680.0% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -2420.326% |
| Simris Alg AB (publ) | 2 Million SEK | -1982.063% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 1267.235% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | -18.082% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 4083.508% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -1233.77% |